PATENT CLAIM ANALYSIS

Application Number: 15948450
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "044000"]

Abstract:
Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.

Claim (Index 38):
The method of  claim 1 , wherein creatinine is reduced in the blood of the subject following administration of the pharmaceutical composition.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 91.0
- Lexical Diversity: 2.11628
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14048827', '14677387', '15606554', '15151290', '15441590']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8358105954327667
- 35 USC 102 Novelty (BERT): 0.5970588703634012
- Combined Prediction Score: 0.8119354229258302
- Mean Citation Score: 559.7868599999998
- Max Citation Score: 620.1012
- Similarity Product: 405.2601345462799

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test